Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v23-FR Version v14-EN
Language French English
Date Updated 2023-05-30 2023-02-14
Drug Identification Number 00804789 00804789
Brand name POTASSIUM PHOSPHATES POTASSIUM PHOSPHATES
Common or Proper name POTASSIUM PO4 POTASSIUM PO4
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients POTASSIUM PHOSPHATE DIBASIC POTASSIUM PHOSPHATE MONOBASIC POTASSIUM PHOSPHATE DIBASIC POTASSIUM PHOSPHATE MONOBASIC
Strength(s) 236MG 224MG 236MG 224MG
Dosage form(s) LIQUID LIQUID
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 10ML 10LIVI 10ML 10LIVI
ATC code B05XA B05XA
ATC description I.V. SOLUTION ADDITIVES I.V. SOLUTION ADDITIVES
Reason for shortage Requirements related to complying with good manufacturing practices. Requirements related to complying with good manufacturing practices.
Anticipated start date
Actual start date 2023-01-16 2022-09-02
Estimated end date 2023-05-15 2023-05-05
Actual end date 2023-05-09
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Baxter item : 6750. Baxter item : 6750. Product is available on allocation based on 100% of historical volumes.
Health Canada comments